APGE Apogee Therapeutics
- 56.710
- -0.600-1.05%
Apogee Therapeutics News
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dambkowski Carl
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer HENDERSON MICHAEL THOMAS
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henderson Jane
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Apogee Therapeutics | 8-K: Current report
Apogee Therapeutics | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers
Apogee Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Apogee Therapeutics | 10-Q: Q2 2024 Earnings Report
Apogee Therapeutics | 8-K: Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dambkowski Carl
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer HENDERSON MICHAEL THOMAS
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer HENDERSON MICHAEL THOMAS
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Dambkowski Carl
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Apogee Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director JONES WILLIAM A JR
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director McKenna Mark C.
Apogee Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Bollinger Lisa
Analysis
Price Target
No Data
No Data